Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

類似資料

• Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
  著者:: Gauthier, Jordan, 等
  出版事項: (2020)
• Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
  著者:: Hay, Kevin A., 等
  出版事項: (2019)
• High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
  著者:: Hirayama, Alexandre V., 等
  出版事項: (2019)
• The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
  著者:: Hirayama, Alexandre V., 等
  出版事項: (2019)
• Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
  著者:: Shadman, Mazyar, 等
  出版事項: (2019)